Heart failure and atrial fibrillation: From basic science to clinical practice

International Journal of Molecular Sciences

Volumn 16, Issue 2, 2015, Pages 3133-3147

  Ferreira, João Pedro ^a,b   Santos, Mário ^a,b  

^a Institute of Biomedical Sciences Abel Salazar   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Atrial fibrillation (AF); Heart failure (HF); Pathophysiology

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; NEUROHORMONE; TRANSCRIPTION FACTOR; ANTICOAGULANT AGENT; CALCIUM; FIBROBLAST GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ANTICOAGULANT THERAPY; ARRHYTHMOGENESIS; BLOOD VESSEL PARAMETERS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; GENE EXPRESSION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEMODYNAMICS; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; OBESITY; PATHOPHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; RISK FACTOR; THROMBOEMBOLISM; ATRIAL FIBRILLATION; EXTRACELLULAR MATRIX; METABOLISM; PATHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CALCIUM; EXTRACELLULAR MATRIX; FIBROBLAST GROWTH FACTORS; HEART FAILURE; HEMODYNAMICS; HUMANS; OBESITY; RENIN-ANGIOTENSIN SYSTEM; TRANSFORMING GROWTH FACTOR BETA;

EID: 84922255160     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16023133     Document Type: Review

References (90)

1. McMurray, J.J.; Adamopoulos, S.; Anker, S.D.; Auricchio, A.; Bohm, M.; Dickstein, K.; Falk, V.; Filippatos, G.; Fonseca, C.; Gomez-Sanchez, M.A. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology: Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail 2012, 14, 803–869.
2. Roubille, F.; Tardif, J.C. New therapeutic targets in cardiology: Heart failure and arrhythmia: HCN Channels. Circulation 2013, 127, 1986–1996.
3. Go, A.S.; Hylek, E.M.; Phillips, K.A.; Chang, Y.; Henault, L.E.; Selby, J.V.; Singer, D.E. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001, 285, 2370–2375.
4. Chugh, S.S.; Roth, G.A.; Gillum, R.F.; Mensah, G.A. Global burden of atrial fibrillation in developed and developing nations. Glob. Heart 2014, 9, 113–119.
5. Wang, T.J.; Larson, M.G.; Levy, D.; Vasan, R.S.; Leip, E.P.; Wolf, P.A.; D’Agostino, R.B.; Murabito, J.M.; Kannel, W.B.; Benjamin, E.J. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The framingham heart study. Circulation 2003, 107, 2920–2925.
6. Carson, P.E.; Johnson, G.R.; Dunkman, W.B.; Fletcher, R.D.; Farrell, L.; Cohn, J.N. The influence of atrial fibrillation on prognosis in mild to moderate heart failure: The V-HeFT studies: The V-HeFT VA cooperative studies group. Circulation 1993, 87, VI102–VI110.
7. Savelieva, I.; John Camm, A. Atrial fibrillation and heart failure: Natural history and pharmacological treatment. Europace 2004, 5 (Suppl. 1), S5–S19.
8. Connolly, S.J.; Ezekowitz, M.D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; Pogue, J.; Reilly, P.A.; Themeles, E.; Varrone, J. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009, 361, 1139–1151.
9. Patel, M.R.; Mahaffey, K.W.; Garg, J.; Pan, G.; Singer, D.E.; Hacke, W.; Breithardt, G.; Halperin, J.L.; Hankey, G.J.; Piccini, J.P. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011, 365, 883–891.
10. Stevenson, W.G.; Stevenson, L.W.; Middlekauff, H.R.; Fonarow, G.C.; Hamilton, M.A.; Woo, M.A.; Saxon, L.A.; Natterson, P.D.; Steimle, A.; Walden, J.A. et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J. Am. Coll. Cardiol. 1996, 28, 1458–1463.
11. Mamas, M.A.; Caldwell, J.C.; Chacko, S.; Garratt, C.J.; Fath-Ordoubadi, F.; Neyses, L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur. J. Heart Fail. 2009, 11, 676–683.
12. Cha, Y.M.; Redfield, M.M.; Shen, W.K.; Gersh, B.J. Atrial fibrillation and ventricular dysfunction: A vicious electromechanical cycle. Circulation 2004, 109, 2839–2843.
13. Burstein, B.; Nattel, S. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol. 2008, 51, 802–809.
14. Nattel, S.; Burstein, B.; Dobrev, D. Atrial remodeling and atrial fibrillation: Mechanisms and implications. Circ. Arrhythm. Electrophysiol. 2008, 1, 62-73.
15. Tsai, C.T.; Lai, LP.; Kuo, K.T.; Hwang, J.J.; Hsieh, C.S.; Hsu, K.L.; Tseng, CD.; Tseng, Y.Z.; Chiang, F.T.; Lin, J.L. Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: Implication for the therapeutic effect of statin in atrial structural remodeling. Circulation 2008, 117, 344-355.
16. Rosenkranz, S. TNF-p1 and angiotensin networking in cardiac remodeling. Cardiovasc. Res. 2004, 63, 423-432.
17. Verheule, S.; Sato, T.; Everett, T.T.; Engle, S.K.; Otten, D.; Rubart-vonder Lohe, M.; Nakajima, HO.; Nakajima, H.; Field, L.J.; Olgin, J.E. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TNF-p1. Circ. Res. 2004, 94, 1458-1465.
18. Liao, C.H.; Akazawa, H.; Tamagawa, M.; Ito, K.; Yasuda, N.; Kudo, Y.; Yamamoto, R.; Ozasa, Y.; Fujimoto, M.; Wang, P. et al. Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts. J. Clin. Investig. 2010, 120, 242-253.
19. Qu, Y.C.; Du, Y.M.; Wu, S.L.; Chen, Q.X.; Wu, H.L.; Zhou, S.F. Activated nuclear factor-KB and increased tumor necrosis factor-a in atrial tissue of atrial fibrillation. Scand. Cardiovasc. J. 2009, 43, 292-297.
20. Adam, O.; Lavall, D.; Theobald, K.; Hohl, M.; Grube, M.; Ameling, S.; Sussman, M.A.; Rosenkranz, S.; Kroemer, H.K.; Schafers, H.J. et al. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J. Am. Coll. Cardiol. 2010, 55, 469-480.
21. Sulciner, D.J.; Irani, K.; Yu, Z.X.; Ferrans, V.J.; Goldschmidt-Clermont, P.; Finkel, T. Rac1 regulates a cytokine-stimulated, redox-dependent pathway necessary for NF-kB activation. Mol. Cell. Biol. 1996, 16, 7115–7121.
22. Gao, G; Dudley, S.C., Jr. Redox regulation, NF-Kb, and atrial fibrillation. Antioxid. Redox Signal. 2009, 11, 2265-2277.
23. Adam, O.; Frost, G; Custodis, F.; Sussman, M.A.; Schafers, H.J.; Bohm, M.; Laufs, U. Role of Rac1 GTPase activation in atrial fibrillation. J. Am. Coll. Cardiol. 2007, 50, 359-367.
24. Goette, A.; Lendeckel, U.; Klein, H.U. Signal transduction systems and atrial fibrillation. Cardiovasc. Res. 2002, 54, 247-258.
25. Brilla, C.G.; Scheer, C; Rupp, H. Angiotensin II and intracellular calcium of adult cardiac fibroblasts. J. Mol. Cell Cardiol. 1998, 30, 1237-1246.
26. Patel, B.M.; Mehta, A.A. Aldosterone and angiotensin: Role in diabetes and cardiovascular diseases. Eur. J. Pharmacol. 2012, 697, 1-12.
27. Harrison, D.G.; Cai, H.; Landmesser, U.; Griendling, K.K. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. 2003, 4, 51-61.
28. Teekakirikul, P.; Eminaga, S.; Toka, O.; Alcalai, R.; Wang, L.; Wakimoto, H; Nayor, M.; Konno, T.; Gorham, J.M.; Wolf, CM. et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TNF-p. J. Clin. Invest. 2010, 120, 3520-3529.
29. Takeda, N.; Manabe, I.; Uchino, Y.; Eguchi, K.; Matsumoto, S.; Nishimura, S.; Shindo, T.; Sano, M.; Otsu, K.; Snider, P. et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Investig. 2010, 120, 254–265.
30. Aleong, R.G.; Sauer, W.H.; Murphy, G.A.; Port, J.D.; Anand, I.S.; Fiuzat, M.; O’Connor, C.M.; Abraham, W.T.; Liggett, S.B.; Bristow, M.R. Prevention of atrial fibrillation by bucindolol is dependent on the β1389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail. 2013, 1, 338–344.
31. Kao, D.P.; Davis, G.; Aleong, R.; O'Connor, C.M.; Fiuzat, M.; Carson, P.E.; Anand, I.S.; Plehn, J.F.; Gottlieb, S.S.; Silver, M.A. et al. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur. J. Heart Fail. 2013, 15, 324–333.
32. Oral, H.; Crawford, T.; Frederick, M.; Gadeela, N.; Wimmer, A.; Dey, S.; Sarrazin, J.F.; Kuhne, M.; Chalfoun, N.; Wells, D. et al. Inducibility of paroxysmal atrial fibrillation by isoproterenol and its relation to the mode of onset of atrial fibrillation. J. Cardiovasc. Electrophysiol. 2008, 19, 466–470.
33. Sharifov, O.F.; Fedorov, V.V.; Beloshapko, G.G.; Glukhov, A.V.; Yushmanova, A.V.; Rosenshtraukh, L.V. Roles of adrenergic and cholinergic stimulation in spontaneous atrial fibrillation in dogs. J. Am. Coll. Cardiol. 2004, 43, 483–490.
34. Wang, C.; Zhang, Y.J.; Wang, Y.L.; Xu, Y.F.; Liu, S.; Chen, Z.Y.; Liu, L.L. Effect of dipfluzine on delayed afterdepolarizations and triggered activity induced by isoprenaline in human atrial fibers. Yao Xue Xue Bao (in Chinese) 2006, 41, 184–187.
35. Van der Velden, H.M.; Ausma, J.; Rook, M.B.; Hellemons, A.J.; van Veen, T.A.; Allessie, M.A.; Jongsma, H.J. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Cardiovasc. Res. 2000, 46, 476–486.
36. Satoh, T.; Zipes, D.P. Unequal atrial stretch in dogs increases dispersion of refractoriness conducive to developing atrial fibrillation. J. Cardiovasc. Electrophysiol. 1996, 7, 833–842.
37. Allessie, M.A.; Boyden, P.A.; Camm, A.J.; Kleber, A.G.; Lab, M.J.; Legato, M.J.; Rosen, M.R.; Schwartz, P.J.; Spooner, P.M.; van Wagoner, D.R.; et al. Pathophysiology and prevention of atrial fibrillation. Circulation 2001, 103, 769–777.
38. Daoud, E.G.; Bogun, F.; Goyal, R.; Harvey, M.; Man, K.C.; Strickberger, S.A.; Morady, F. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996, 94, 1600–1606.
39. Hasenfuss, G.; Reinecke, H.; Studer, R.; Meyer, M.; Pieske, B.; Holtz, J.; Holubarsch, C.; Posival, H.; Just, H.; Drexler, H. Relation between myocardial function and expression of sarcoplasmic reticulum Ca2+-ATPase in failing and nonfailing human myocardium. Circ. Res. 1994, 75, 434–442.
40. Voigt, N.; Li, N.; Wang, Q.; Wang, W.; Trafford, A.W.; Abu-Taha, I.; Sun, Q.; Wieland, T.; Ravens, U.; Nattel, S. et al. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+–Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. Circulation 2012, 125, 2059–2070.
41. Hove-Madsen, L.; Llach, A.; Bayes-Genis, A.; Roura, S.; Rodriguez Font, E.; Aris, A.; Cinca, J. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation 2004, 110, 1358–1363.
42. Neef, S.; Dybkova, N.; Sossalla, S.; Ort, K.R.; Fluschnik, N.; Neumann, K.; Seipelt, R.; Schondube, F.A.; Hasenfuss, G.; Maier, L.S. CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ. Res. 2010, 106, 1134–1144.
43. Voigt, N.; Heijman, J.; Wang, Q.; Chiang, D.Y.; Li, N.; Karck, M.; Wehrens, X.H.; Nattel, S.; Dobrev, D. Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation 2014, 129, 145–156.
44. Mathew, J.S.; Sachs, M.C.; Katz, R.; Patton, K.K.; Heckbert, S.R.; Hoofnagle, A.N.; Alonso, A.; Chonchol, M.; Deo, R.; Ix, J.H. et al. Fibroblast growth factor-23 and incident atrial fibrillation: The multi-ethnic study of atherosclerosis (MESA) and the cardiovascular health study (CHS). Circulation 2014, 130, 298–307.
45. Gutierrez, O.M.; Januzzi, J.L.; Isakova, T.; Laliberte, K.; Smith, K.; Collerone, G.; Sarwar, A.; Hoffmann, U.; Coglianese, E.; Christenson, R. et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119, 2545–2552.
46. Rosenberg, M.A.; Manning, W.J. Diastolic dysfunction and risk of atrial fibrillation: A mechanistic appraisal. Circulation 2012, 126, 2353–2362.
47. Gupta, D.K.; Shah, A.M.; Giugliano, R.P.; Ruff, C.T.; Antman, E.M.; Grip, L.T.; Deenadayalu, N.; Hoffman, E.; Patel, I.; Shi, M. et al. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. Eur. Heart J. 2014, 35, 1457–1465.
48. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008, 39, 1901–1910.
49. Dittrich, H.C.; Pearce, L.A.; Asinger, R.W.; McBride, R.; Webel, R.; Zabalgoitia, M.; Pennock, G.D.; Safford, R.E.; Rothbart, R.M.; Halperin, J.L. et al. Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study: Stroke prevention in atrial fibrillation investigators. Am. Heart J. 1999, 137, 494–499.
50. Gage, B.F.; Waterman, A.D.; Shannon, W.; Boechler, M.; Rich, M.W.; Radford, M.J. Validation of clinical classification schemes for predicting stroke: Results from the national registry of atrial fibrillation. JAMA 2001, 285, 2864–2870.
51. Atrial Fibrillation Investigayors. Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials. Arch. Intern. Med. 1998, 158, 1316–1320.
52. Kenchaiah, S.; Evans, J.C.; Levy, D.; Wilson, P.W.; Benjamin, E.J.; Larson, M.G.; Kannel, W.B.; Vasan, R.S. Obesity and the risk of heart failure. N. Engl. J. Med. 2002, 347, 305–313.
53. Morricone, L.; Malavazos, A.E.; Coman, C.; Donati, C.; Hassan, T.; Caviezel, F. Echocardiographic abnormalities in normotensive obese patients: Relationship with visceral fat. Obes. Res. 2002, 10, 489–498.
54. Psaty, B.M.; Manolio, T.A.; Kuller, L.H.; Kronmal, R.A.; Cushman, M.; Fried, L.P.; White, R.; Furberg, C.D.; Rautaharju, P.M. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997, 96, 2455–2461.
55. Lin, Y.K.; Chen, Y.J.; Chen, S.A. Potential atrial arrhythmogenicity of adipocytes: Implications for the genesis of atrial fibrillation. Med. Hypotheses 2010, 74, 1026–1029.
56. Nagashima, K.; Okumura, Y.; Watanabe, I.; Nakai, T.; Ohkubo, K.; Kofune, M.; Mano, H.; Sonoda, K.; Hiro, T.; Nikaido, M. et al. Does location of epicardial adipose tissue correspond to endocardial high dominant frequency or complex fractionated atrial electrogram sites during atrial fibrillation? Circ. Arrhythm. Electrophysiol. 2012, 5, 676–683.
57. Chen, P.S.; Turker, I. Epicardial adipose tissue and neural mechanisms of atrial fibrillation. Circ. Arrhythm. Electrophysiol. 2012, 5, 618–620.
58. Batal, O.; Schoenhagen, P.; Shao, M.; Ayyad, A.E.; van Wagoner, D.R.; Halliburton, S.S.; Tchou, P.J.; Chung, M.K. Left atrial epicardial adiposity and atrial fibrillation. Circ. Arrhythm. Electrophysiol. 2010, 3, 230–236.
59. Lin, Y.K.; Chen, Y.C.; Chang, S.L.; Lin, Y.J.; Chen, J.H.; Yeh, Y.H.; Chen, S.A.; Chen, Y.J. Heart failure epicardial fat increases atrial arrhythmogenesis. Int. J. Cardiol. 2013, 167, 1979–1983.
60. Chen, Y.J.; Tai, C.T.; Chiou, C.W.; Wen, Z.C.; Chan, P.; Lee, S.H.; Chen, S.A. Inducibility of atrial fibrillation during atrioventricular pacing with varying intervals: Role of atrial electrophysiology and the autonomic nervous system. J. Cardiovasc. Electrophysiol. 1999, 10, 1578–1585.
61. Aydin, H.; Toprak, A.; Deyneli, O.; Yazici, D.; Tarcin, O.; Sancak, S.; Yavuz, D.; Akalin, S. Epicardial fat tissue thickness correlates with endothelial dysfunction and other cardiovascular risk factors in patients with metabolic syndrome. Metab. Syndr. Relat. Disord. 2010, 8, 229–234.
62. Pinto, A.; Tuttolomondo, A.; Casuccio, A.; di Raimondo, D.; di Sciacca, R.; Arnao, V.; Licata, G. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin. Sci. (Lond.) 2009, 116, 781–789.
63. Acevedo, M.; Corbalan, R.; Braun, S.; Pereira, J.; Gonzalez, I.; Navarrete, C. Biochemical predictors of cardiac rhythm at 1 year follow-up in patients with non-valvular atrial fibrillation. J. Thromb. Thrombolysis 2012, 33, 383–388.
64. Girerd, N.; Scridon, A.; Bessiere, F.; Chauveau, S.; Geloen, A.; Boussel, L.; Morel, E.; Chevalier, P. Periatrial epicardial fat is associated with markers of endothelial dysfunction in patients with atrial fibrillation. PLoS One 2013, 8, e77167.
65. Khan, R.S.; Kato, T.S.; Chokshi, A.; Chew, M.; Yu, S.; Wu, C.; Singh, P.; Cheema, F.H.; Takayama, H.; Harris, C. et al. Adipose tissue inflammation and adiponectin resistance in patients with advanced heart failure: Correction after ventricular assist device implantation. Circ. Heart Fail. 2012, 5, 340–348.
66. Vazquez-Vela, M.E.; Torres, N.; Tovar, A.R. White adipose tissue as endocrine organ and its role in obesity. Arch. Med. Res. 2008, 39, 715–728.
67. Fei, J.; Cook, C.; Blough, E.; Santanam, N. Age and sex mediated changes in epicardial fat adipokines. Atherosclerosis 2010, 212, 488–494.
68. Lavie, C.J.; Milani, R.V.; Ventura, H.O. Obesity and cardiovascular disease: Risk factor, paradox, and impact of weight loss. J. Am. Coll. Cardiol. 2009, 53, 1925–1932.
69. Fontes-Carvalho, R.; Fontes-Oliveira, M.; Sampaio, F.; Mancio, J.; Bettencourt, N.; Teixeira, M.; Rocha Goncalves, F.; Gama, V.; Leite-Moreira, A. Influence of epicardial and visceral fat on left ventricular diastolic and systolic functions in patients after myocardial infarction. Am. J. Cardiol. 2014, 114, 1663–1669.
70. Canepa, M.; Strait, J.B.; Abramov, D.; Milaneschi, Y.; AlGhatrif, M.; Moni, M.; Ramachandran, R.; Najjar, S.S.; Brunelli, C.; Abraham, T.P. et al. Contribution of central adiposity to left ventricular diastolic function (from the baltimore longitudinal study of aging). Am. J. Cardiol. 2012, 109, 1171–1178.
71. Russo, C.; Jin, Z.; Homma, S.; Rundek, T.; Elkind, M.S.; Sacco, R.L.; di Tullio, M.R. Effect of obesity and overweight on left ventricular diastolic function: A community-based study in an elderly cohort. J. Am. Coll. Cardiol. 2011, 57, 1368–1374.
72. Konishi, M.; Sugiyama, S.; Sugamura, K.; Nozaki, T.; Matsubara, J.; Akiyama, E.; Utsunomiya, D.; Matsuzawa, Y.; Yamashita, Y.; Kimura, K. et al. Accumulation of pericardial fat correlates with left ventricular diastolic dysfunction in patients with normal ejection fraction. J. Cardiol. 2012, 59, 344–351.
73. Chugh, S.S.; Blackshear, J.L.; Shen, W.K.; Hammill, S.C.; Gersh, B.J. Epidemiology and natural history of atrial fibrillation: Clinical implications. J. Am. Coll. Cardiol. 2001, 37, 371–378.
74. Arnar, D.O.; Thorvaldsson, S.; Manolio, T.A.; Thorgeirsson, G.; Kristjansson, K.; Hakonarson, H.; Stefansson, K. Familial aggregation of atrial fibrillation in iceland. Eur. Heart J. 2006, 27, 708–712.
75. Ellinor, P.T.; Lunetta, K.L.; Albert, C.M.; Glazer, N.L.; Ritchie, M.D.; Smith, A.V.; Arking, D.E.; Muller-Nurasyid, M.; Krijthe, B.P.; Lubitz, S.A. et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat. Genet. 2012, 44, 670–675.
76. Duygu, B.; Poels, E.M.; da Costa Martins, P.A. Genetics and epigenetics of arrhythmia and heart failure. Front. Genet. 2013, 4, 219.
77. Finsterer, J.; Stollberger, C.; Keller, H. Arrhythmia-related workup in hereditary myopathies. J. Electrocardiol. 2012, 45, 376–384.
78. Corley, S.D.; Epstein, A.E.; DiMarco, J.P.; Domanski, M.J.; Geller, N.; Greene, H.L.; Josephson, R.A.; Kellen, J.C.; Klein, R.C.; Krahn, A.D. et al. Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 2004, 109, 1509–1513.
79. Roy, D.; Talajic, M.; Nattel, S.; Wyse, D.G.; Dorian, P.; Lee, K.L.; Bourassa, M.G.; Arnold, J.M.; Buxton, A.E.; Camm, A.J. et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med. 2008, 358, 2667–2677.
80. Shelton, R.J.; Clark, A.L.; Goode, K.; Rigby, A.S.; Houghton, T.; Kaye, G.C.; Cleland, J.G. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II study). Heart 2009, 95, 924–930.
81. Hagens, V.E.; Ranchor, A.V.; van Sonderen, E.; Bosker, H.A.; Kamp, O.; Tijssen, J.G.; Kingma, J.H.; Crijns, H.J.; van Gelder, I.C. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: Results from the rate control versus electrical cardioversion (RACE) study. J. Am. Coll. Cardiol. 2004, 43, 241–247.
82. Camm, A.J.; Kirchhof, P.; Lip, G.Y.; Schotten, U.; Savelieva, I.; Ernst, S.; van Gelder, I.C.; Al-Attar, N.; Hindricks, G.; Prendergast, B. et al. Guidelines for the management of atrial fibrillation: The task force for the management of atrial fibrillation of the european society of cardiology (ESC). Eur. Heart J. 2010, 31, 2369–2429.
83. Wolf, P.A.; Abbott, R.D.; Kannel, W.B. Atrial fibrillation as an independent risk factor for stroke: The framingham study. Stroke 1991, 22, 983–988.
84. Pedersen, O.D.; Bagger, H.; Kober, L.; Torp-Pedersen, C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999, 100, 376–380.
85. Ducharme, A.; Swedberg, K.; Pfeffer, M.A.; Cohen-Solal, A.; Granger, C.B.; Maggioni, A.P.; Michelson, E.L.; McMurray, J.J.; Olsson, L.; Rouleau, J.L. et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program. Am. Heart J. 2006, 151, 985–991.
86. Nasr, I.A.; Bouzamondo, A.; Hulot, J.S.; Dubourg, O.; le Heuzey, J.Y.; Lechat, P. Prevention of atrial fibrillation onset by β-blocker treatment in heart failure: A meta-analysis. Eur. Heart J. 2007, 28, 457–462.
87. Swedberg, K.; Zannad, F.; McMurray, J.J.; Krum, H.; van Veldhuisen, D.J.; Shi, H.; Vincent, J.; Pitt, B. Eplerenone and atrial fibrillation in mild systolic heart failure: Results from the EMPHASIS-HF (eplerenone in mild patients hospitalization and survival study in heart failure) study. J. Am. Coll. Cardiol. 2012, 59, 1598–1603.
88. Wilton, S.B.; Leung, A.A.; Ghali, W.A.; Faris, P.; Exner, D.V. Outcomes of cardiac resynchronization therapy in patients with versus those without atrial fibrillation: A systematic review and meta-analysis. Heart Rhythm. 2011, 8, 1088–1094.
89. Lopes, C.; Pereira, T.; Barra, S. Cardiac resynchronization therapy in patients with atrial fibrillation: A meta-analysis. Rev. Port. Cardiol. 2014, 33, 717–725.
90. Brignole, M.; Auricchio, A.; Baron-Esquivias, G.; Bordachar, P.; Boriani, G.; Breithardt, O.A.; Cleland, J.; Deharo, J.C.; Delgado, V.; Elliott, P.M. et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The task force on cardiac pacing and resynchronization therapy of the european society of cardiology (ESC): Developed in collaboration with the european heart rhythm association (EHRA). Eur. Heart J. 2013, 15, 1070–1118.